CD133 (Prominin-1) Antibody PE 12-1338-42 from Thermo Fisher Scientific

Published Figures
Supplier Images

Register or Sign In to View Figures.

Oncotarget
May 25 2018

Fig 1: Fap1-inhibition with SLV peptide increases Fas and Gsk3ß phosphorylation in CD133+ cells in a murine xenograft modelSW620 cells were injected in the flanks of athymic Nude mice and tumor volume was determination biweekly. Mice were treated weekly with oxaliplatin (days 0, 7 and 14) and injected daily with Fap1 blocking SLV peptide or VLS control peptide, or treated with SLV or VLS peptide alone (n=12 per cohort). Tumors were simultaneously harvested from cohorts of mice when control tumors were >2,000 mm3. (A) SLV peptide increases Fas phosphorylation in CD133+ xenograft tumors with or without oxaliplatin. Immunofluorescent detection of phospho-Fas or CD133 was performed with DAPI staining of nuclei. (B) SLV peptide increases Gsk3ß phosphorylation in CD133+ xenograft tumors with or without oxaliplatin. Immunofluorescent detection of phospho-Gsk3ß or CD133 was performed with DAPI staining of nuclei.
Register or Sign In to View Figures.

Oncotarget
May 25 2018

Fig 2: Treatment with oxaliplatin decreases total SW480 or SW620 cells, but increases the relative number of CD133+ cells in these lines(A) SW480 and SW620 cells were analyzed by flow cytometry for CD133+ cells with versus without oxaliplatin treatment. Histograms were gated using unstained cells as a control. (B) Oxaliplatin treatment decreased the total number of SW480 or SW620 cells, but the number of CD133+ cells were relatively unaffected. Absolute numbers of cells under the various conditions were determined. Statistically significant differences are indicated by *, **, ***, #, or ## (p<0.0001, n=6 for all comparisons). (C) The percent of CD133+ cells was determined before or after oxaliplatin treatment in both lines. Significant differences indicated by *, **, ***, or # (p<0.001, n=6 for all comparisons).
Register or Sign In to View Figures.

Oncotarget
May 25 2018

Fig 3: Fap1 expression is increased in CD133+ colon cancer cells and the PTPN13 promoter is regulated by Irf2(A) Expression of Fap1 is correlated with CD133+ cell abundance in colon cancer cell lines. Total SW480 or SW620 cells, or CD133+ cells isolated from these lines, were analyzed for Fap1 mRNA by real time PCR. Significant differences are indicated by *, **, ***, #, ##, or ### (p<0.01, n=6 for all comparisons). (B) Fap1 protein is more abundant in CD133+ cells vs CD133- cells. CD133+ cells that were isolated from the SW620 line were compared to CD133- cells by Western blot of total lysate proteins. Blots were probed from Fap1 and Tubulin (as a loading control). (C) Irf2 expression is decreased in CD133+ cells vs the total SW480 or SW620 cell population, and significantly less Icsbp is expressed in these cells compared to Irf2. Total SW480 or SW620 cells, or CD133+ cells isolated from these lines, were analyzed for Icsbp or Irf2 mRNA by real time PCR. Significant differences are indicated by *, **, ***, or # (p<0.01, n=6 for all comparisons). (D) Irf2 represses the PTPN13 promoter. SW620 cells were transfected with a construct with 1.0 kb of PTPN13 promoter linked to a luciferase reporter and vectors to overexpress Icsbp, wild type Irf2, or Y109F-Irf2 (versus empty control vector), or to knockdown Icsbp or Irf2 (with specific shRNA versus scrambled shRNA vector). Significant differences indicated by *, **, or *** (p<0.001, n=6 for all comparisons). (E) Irf2 represses the Icsbp-binding cis element from the PTPN13 promoter. SW620 cells were transfected with a construct with three copies of the previously identified PTPN13 cis element linked to a minimal promoter and luciferase reporter. Cells were co-transfected with vectors to overexpress or knockdown Icsbp or Irf2, as described above. Significant differences indicated by *, **, or *** (p<0.001, n=6 for all comparisons).
Register or Sign In to View Figures.

Oncotarget
May 25 2018

Fig 4: Fap1-inhibition increased Fas or oxaliplatin induced apoptosis in CD133+ colon cancer cells(A) Fap1-blocking SLV peptide increases Fas-induced apoptosis. Total SW480 or SW620 cells were treated with SLV peptide (or VLS control), with or without Fas-agonist antibody, and analyzed for apoptosis by Annexin V staining. Significant differences indicated by *, **, or *** (p<0.01, n=4 for all comparisons). (B) Fap1-inhibition increases Fas or oxaliplatin induced apoptosis in CD133+ SW620 cells. CD133+ SW620 cells were analyzed for apoptosis by Annexin V staining, with or without Fas-agonist antibody. Some cells were treated with SLV peptide (or VLS control) or transduced with a vector to express Fap1 specific shRNAs (or scrambled control). Significant differences indicated by *, **, ***, or # (p<0.001, n=4 for all comparisons). (C) Fap1-inhibition increases Fas induced caspase 8 cleavage in CD133+ SW620 cells. Cells were analyzed by ELISA for cleavage of caspase 8 (death receptor induced apoptosis). Statistically significant differences indicated by * or ** (p<0.001, n=4). (D) Oxaliplatin treatment increases caspase 9 cleavage in CD133+ SW620 cells. Cells were analyzed by ELISA for cleavage of caspase 9 (intrinsic apoptosis). Statistically significant differences indicated by *, **, ***, or # (p<0.001, n=4). (E) Plasma membrane expression of Fas was not altered by SLV peptide or oxaliplatin treatment of CD133+ SW620 cells. Western blots of cell lysates were probed for Fas or Na+/K+ ATPase (as a loading control). (F) Fap1 inhibition increases Fas or oxaliplatin induced apoptosis in CD133+ SW480 cells. Similar experiments were performed with the SW480 cell line. Statistically significant differences are indicated by * or ** (p<0.001, n=6 for both comparisons).
Register or Sign In to View Figures.

Oncotarget
May 25 2018

Fig 5: Fap1-inhibition decreases abundance of CD133+CD44+ cells in in a murine xenograft model of colon cancer with or without oxaliplatinTumors from the mice described above were analyzed for cell population distribution after various treatments. (A) Histograms from flow cytometry demonstrate decreased abundance of CD133+CD44+ cells after treatment with SLV peptide with or without oxaliplatin. A representative histograms for each cohort is shown. (B) Treatment with SLV peptide decreases relative abundance of CD133+CD44+ cells in xenograft tumors. Tumors were simultaneously harvested from mice treated with SLV peptide versus VLS control (when control group tumors were >2,000 mm3) and analyzed for CD133 and CD44 expression by flow cytometry. Significant differences indicated by *, **, or ***. (p<0.001, n=6). (C) The addition of SLV peptide to oxaliplatin treatment decreases relative abundance of CD133+CD44+ cells in xenograft tumors. Tumors were simultaneously harvested from mice treated with oxaliplatin + SLV peptide versus VLS control (when control group tumors were >2,000 mm3) and analyzed for CD133 and CD44 expression by flow cytometry. Significant differences indicated by *, **, or ***. (p<0.001, n=6).

Be the first to write a review!

Citations:

(18)

Figures:

Supplier Page

Supplier Page from
Thermo Fisher Scientific for
CD133 (Prominin-1) Antibody PE

Thermo Fisher Scientific's CD133 (Prominin-1) Antibody PE is a Mouse monoclonal antibody. The CD133 (Prominin-1) Antibody PE was generated using PROM1 as the antigen. It reacts with Homo Sapiens, and Human. This antibody has been shown to work in applications such as: Flow Cytometry.

Product Specs
ItemCD133 (Prominin-1) Antibody PE
CompanyThermo Fisher Scientific
Price Pricing Info Supplier Page View Company Product Page
Catalog Number12-1338-42
Quantity100 Tests
ApplicationsFlow Cytometry
Concentration5 µL/Test
Conjugate/TagPE
FormatPBS with 0.2% BSA and 0.09% sodium azide; pH 7.2
ReactivityHuman
TargetCD133 (Prominin-1)
IsotypeIgG1 kappa
CloneTMP4
HostMouse
NCBI Full Gene Nameprominin 1
NCBI Gene AliasesAC133, CD133, CORD12, MCDR2, MSTP061, PROML1, RP41, STGD4
ClonalityMonoclonal
PurityAffinity chromatography
Storage Temperature4° C, store in dark, DO NOT FREEZE!
Antibody TypePrimary
Storage4° C, store in dark, DO NOT FREEZE!

Add to Compare List

Thermo Fisher Scientific

81 Wyman Street

Waltham, MA 02451

United States

Phone: 800-678-5599
Fax: 800-331-2286

Company Profile

Website: www.thermofisher.com

(1) Human Adult Renal Progenitor Cells Prevent Cisplatin-Nephrotoxicity by Inducing CYP1B1 Overexpression and miR-27b-3p Down-Regulation through Extracellular VesiclesCellsJune 17, 2023Rossana Franzin, Alessandra Stasi, Giuseppe De Palma, Angela Picerno, Claudia Curci, Serena Sebastiano, Monica Campioni, Antonella Cicirelli, Alessandro Rizzo, Vito Francesco Di Lorenzo, et al.Fluor 488 goat anti-mouse IgG. Human CD133 (Prominin-1) mouse anti-human monoclonal Ab (TMP4) PE (#12-1338-42,Invitrogen) was used to perform direct immunolabeling. All cells and sections were counterstained with

(2) A local water molecular-heating strategy for near-infrared long-lifetime imaging-guided photothermal therapy of glioblastomaNature CommunicationsMay 13, 2023Dongkyu Kang, Hyung Shik Kim, Soohyun Han, Yeonju Lee, Young-Pil Kim, Dong Yun Lee, Joonseok Lee4-(N-maleimidomethyl) cyclohexane-1-carboxylate (sulfo-SMCC), and CD133 (Prominin-1) monoclonal antibody (12-1338-42) was purchased from Thermo Fisher Scientific, Waltham, MA, USA. An Amicon Ultra centrifugal filter (0.5

(3) Lipogenesis promotes mitochondrial fusion and maintains cancer stemness in human NSCLCJCI insightMarch 22, 2023Liu Z, Lei J, Wu T, Hu W, Zheng M, Wang Y, Song J, Ruan H, Xu L, Ren T, et al.at room temperature with the following antibodies: PE-conjugated anti-CD133 antibody (eBiosciences, 12-1338-42), anti–human OPA1 antibody (Cell Signaling Technology, 67589), and anti–human SPDEF antibody (Santa Cruz Biotechnology Inc

(4) Non-canonical Wnt/Ca2+ signaling is essential to promote self-renewal and proliferation in colon cancer stem cellsFrontiers in OncologyMarch 10, 2023Miguel Angel Sarabia-Sánchez, Angela Patricia Moreno-Londoño, María Cristina Castañeda-Patlán, Eduardo Alvarado-Ortiz, Juan Carlos Martínez-Morales, Martha Robles-Floresor sphere culture. The cells were incubated for 30 min at 4°C as follows: CD133-PE-coupled (Cat. No. 12-1338-42 eBioscience), CD44-APC-coupled (559942 BD Pharmingen), and CD44v6 (Cat. No. BMS125 eBioscience). In

(5) Suppression of Cancer Cell Stemness and Drug Resistance via MYC Destabilization by Deubiquitinase USP45 Inhibition with a Natural Small MoleculeCancersFebruary 1, 2023Tu X, Li C, Sun W, Tian X, Li Q, Wang S, Ding X, Huang Z.buffer (00440942, Invitrogen, Carlsbad, CA, USA). The cells were incubated with CD133-PE antibody (12-1338-42, Invitrogen, Carlsbad, CA, USA) for 30 min at 4 °C. The cells were then washed twice with staining buffer

(6) Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancerJournal of experimental & clinical cancer research : CRSeptember 22, 2021Liu C, Pan Z, Chen Q, Chen Z, Liu W, Wu L, Jiang M, Lin W, Zhang Y, Lin W, et al.Biotech, Jiangsu, China), Propidiumiodide (KGA512, Keygen Biotech, Jiangsu, China) or CD133 antibody (12-1338-42, eBioscience, invitrogen), SOX2 antibody (50-9811-82, eBioscience, invitrogen) were added to the cell

(7) Profiling and Targeting of Energy and Redox Metabolism in Grade 2 Bladder Cancer Cells with Different Invasiveness PropertiesCellsDecember 11, 2020Pasquale V, Ducci G, Campioni G, Ventrici A, Assalini C, Busti S, Vanoni M, Vago R, Sacco E.with conjugated antibody CD44-APC (cod. 17-0441-82 eBioscience™, San Diego, CA, USA), CD133-PE (cod. 12-1338-42 eBioscience™), and Aldefluor, Stem Cell Identification Kit (STEMCELL Technologies™, Vancouver, BC, Canada) according

(8) Human umbilical cord-derived mesenchymal stem cells and human cord blood mononuclear cells protect against cisplatin-induced acute kidney injury in rat modelsExperimental and therapeutic medicineDecember 1, 2020Xu Q, Yan P, Duan XJ, Wu X, Chen XJ, Luo M, Peng JC, Feng LX, Liu J, Zhong HL, et al.cat. no. 11‑0459‑42; 5 µl/ml), CD34 (eFluor ® 450; cat. no. 48‑0349‑42; 5 µl/ml), CD133 (PE; cat. no. 12‑1338‑42; 5 µl/ml), provided by Thermo Fishier Scientific. Inc., were used for flow cytometry. The cells were

(9) Chemerin enhances the adhesion and migration of human endothelial progenitor cells and increases lipid accumulation in mice with atherosclerosisLipids in health and diseaseSeptember 20, 2020Jia J, Yu F, Xiong Y, Wei W, Ma H, Nisi F, Song X, Yang L, Wang D, Yuan G, et al.

(10) The Deubiquitinase USP4 Stabilizes Twist1 Protein to Promote Lung Cancer Cell StemnessCancersJune 15, 2020Li F, Hu Q, He T, Xu J, Yi Y, Xie S, Ding L, Fu M, Guo R, Xiao ZJ, et al.cell numbers were counted. Cells were incubated with Phycoerythrin (PE) conjugated anti-CD133 antibody (12-1338-42, Invitrogen, Carlsbad, CA, USA) or PE conjugated IgG1 kappa isotype control antibody (12-4714-81, Invitrogen,

(11) SUL-109 Protects Hematopoietic Stem Cells from Apoptosis Induced by Short-Term Hypothermic Preservation and Maintains Their Engraftment PotentialBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationApril 1, 2020Aerts-Kaya FSF, Visser TP, Pervin B, Mammadova A, Özyüncü Ö, Wagemaker G, Uçkan-Çetinkaya FD.

(12) IDH1‑R132H mutation radiosensitizes U87MG glioma cells via epigenetic downregulation of TIGAROncology LettersNovember 25, 2019Narui Yin, Ting Xie, Haowen Zhang, Jian Chen, Jiahua Yu, Fenju Liuat 4˚C with phycoerythrin‑conjugated CD133 antibody (1:100, Thermo Fisher Scientific, Inc.; cat. no. 12‑1338‑42). U87MG‑GSCs were sorted using a FACScalibur flow cytometer (BD Biosciences). Cells were irradiated

(13) Inhibition of Fas associated phosphatase 1 (Fap1) facilitates apoptosis of colon cancer stem cells and enhances the effects of oxaliplatinOncotargetMay 25, 2018Huang W, Bei L, Eklund EA.incubated with PE-conjugated anti-CD133 and/or FITC-conjugated anti-CD44 (eBioscience, San Diego, CA; 12-1338-42 and 11-0441-82). Labeled cells were analyzed by LSR Fortessa Cell Analyzer (BD Bioscience). Data was

(14) ING5 activity in self-renewal of glioblastoma stem cells via calcium and follicle stimulating hormone pathwaysOncogeneJanuary 18, 2018Wang F, Wang AY, Chesnelong C, Yang Y, Nabbi A, Thalappilly S, Alekseev V, Riabowol K.

(15) Modified Leukocyte Filter Removes Tumor Cells from the Salvaged BloodPloS oneJanuary 1, 2015Mei K, Du L, Yan M, Zhang Z, Zhang F, Gong L, Sun K, Zhang J, Tang Y, Jiang C, et al.[15,16]. To further identify clones or invasive growth cells in hepatoma samples, CD133-FITC (Cat: 12-1338-42, eBioscience, USA) was selected in protocols 2 and 3 (n = 7 in each) [15, 16, 19– 21]. The glass slides

(16) Comparative evaluation of differentiation potential of menstrual blood- versus bone marrow-derived stem cells into hepatocyte-like cellsPloS oneJanuary 1, 2014Khanjani S, Khanmohammadi M, Zarnani AH, Akhondi MM, Ahani A, Ghaempanah Z, Naderi MM, Eghtesad S, Kazemnejad S.

(17) Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cellsPloS oneJanuary 1, 2014Sahlberg SH, Spiegelberg D, Glimelius B, Stenerlöw B, Nestor M.

(18) Established breast cancer stem cell markers do not correlate with in vivo tumorigenicity of tumor-initiating cellsInternational journal of oncologyDecember 1, 2012Lehmann C, Jobs G, Thomas M, Burtscher H, Kubbies M.

Be the First to Write a Review!

Oncotarget

Oncotarget

Oncotarget

Oncotarget

Oncotarget

CD133 (Prominin-1) Antibody PE from Thermo Fisher Scientific

Thermo Fisher Scientific

Citations (18)

Reviews

CD133 (Prominin-1) Antibody PE from Thermo Fisher Scientific

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map